B
Bull
Bull · 25%NNNN
$51.40
Scenario price
$3.270
+0.146 (+4.47%)At close
Loading chart…
- High
- 3.450
- Open
- 3.200
- VWAP
- 3.31
- Volume
- 56.45K
- Mkt Cap
- —
- Low
- 3.200
- Amount
- 186.66K
- EV/EBITDA, TTM
- 0.00
Anbio Biotechnology is a Germany-based medical device company. The Company is engaged in the development of medical technology and the provision of in vitro diagnostics (IVD) products. Its products offer solutions for over the counter (OTC) use, point-of-care (POCT) settings, and laboratory applications, ensuring that both healthcare providers and patients have access to reliable and efficient diagnostic tools in any setting. Its IVD products detect a wide range of biomarkers across critical medical fields, including infectious diseases, cancer, cardiovascular diseases, inflammation, drug abuse, endocrine disorders, renal disease, pharmacogenomics, and diabetes. Some of its IVD platforms: Chemiluminescence Immunoassay (ChLIA), Lateral Flow Immunoassay (LFIA), Fluorescent Immunoassay (FIA), Polymerase Chain Reaction (PCR) and Loop-mediated Isothermal Amplification (LAMP).
AI analysis of Anbio Biotechnology (NNNN)
SellAnbio Biotechnology (NNNN) is not a good buy right now due to its significant price decline and poor technical indicators. The current price is $3.13, which has dropped 89.38% year-to-date and 40.38% over the past 20 days. Additionally, the RSI is extremely low at 6.77, indicating oversold conditions, but this could suggest further downside risk rather than an immediate buying opportunity. The forward P/E ratio is currently at 0, which may indicate uncertainty about future earnings, and the gross margin is high at 92.32% for Q2 2025, but this is overshadowed by the overall negative performance and market sentiment.
Valuation Metrics
The current forward P/E ratio for Anbio Biotechnology (NNNN) is 0.00, compared to its 5-year average forward P/E of 0.00.
Alphio AI Price Scenarios for NNNN
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.
Events Timeline
News
8.507-09Yahoo FinanceAnbio Biotechnology Files Shelf Registration Statement
4.501-16Barron'sS&P 500 Futures Rise in Pre-Market Trading; QXO and Mosaic Underperform
2.012-04BenzingaUiPath Shares Rise Approximately 9%; Check Out 20 Stocks Making Moves in Premarket Trading
5.008-09NewsfilterAnbio Biotechnology Responds to Global Outbreaks with Chikungunya Rapid Test and New 15-Minute Ultra-Fast PCR System
5.008-09Yahoo FinanceAnbio Biotechnology Responds to Global Outbreaks with Chikungunya Rapid Test and New 15-Minute Ultra-Fast PCR System
NNNN FAQ — answered by Alphio AI
Anbio Biotechnology is a Germany-based medical device company. The Company is engaged in the development of medical technology and the provision of in vitro diagnostics (IVD) products. Its products offer solutions for over the counter (OTC) use, point-of-care (POCT) settings, and laboratory applications, ensuring that both healthcare providers and patients have access to reliable and efficient diagnostic tools in any setting. Its IVD products detect a wide range of biomarkers across critical medical fields, including infectious diseases, cancer, cardiovascular diseases, inflammation, drug abuse, endocrine disorders, renal disease, pharmacogenomics, and diabetes. Some of its IVD platforms: Chemiluminescence Immunoassay (ChLIA), Lateral Flow Immunoassay (LFIA), Fluorescent Immunoassay (FIA), Polymerase Chain Reaction (PCR) and Loop-mediated Isothermal Amplification (LAMP). It operates in the Healthcare sector.
Anbio Biotechnology (NNNN) is not a good buy right now due to its significant price decline and poor technical indicators. The current price is $3.13, which has dropped 89.38% year-to-date and 40.38% over the past 20 days. Additionally, the RSI is extremely low at 6.77, indicating oversold conditions, but this could suggest further downside risk rather than an immediate buying opportunity. The forward P/E ratio is currently at 0, which may indicate uncertainty about future earnings, and the gross margin is high at 92.32% for Q2 2025, but this is overshadowed by the overall negative performance and market sentiment.
Community
More ↗No posts yet
Sign up or log in to join the discussionThis page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.